Yokogawa to Supply Energy Management System for Yuri Green Hydrogen Project in Australia
5.9.2023 03:00:00 EEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Australia has received an order from Monford Group Pty Ltd. to supply an energy management system (EMS) for the initial phase (“phase 0”) of the Yuri Green Hydrogen Project (hereafter, Yuri), which is constructing an industrial-scale renewable hydrogen production complex in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904401589/en/
Conceptual drawing showing the Yuri project facilities at the completion of phase 0. The existing YPF ammonia plant is in the foreground and the solar plant is in the background. (Source: ENGIE S.A.)
The Yuri project is being undertaken in the Pilbara region of Western Australia by Yuri Operations Pty Ltd, a joint venture between ENGIE Renewables Australia Pty Ltd and Mitsui & Co., Ltd. A consortium consisting of the engineering, procurement, construction and commissioning (EPCC) companies Technip Energies and Monford Group Pty Ltd. is constructing these facilities, which will consist of an 18-megawatt solar power plant, an 8-megawatt battery energy storage system (BESS), and a 10-megawatt electrolyzer. Using carbon-free solar energy, this facility will be able to produce up to 640 tons of green hydrogen per year. The hydrogen will be used as a feedstock to produce green ammonia at an adjacent ammonia plant operated by Yara Pilbara Fertiliser Pty Ltd (YPF). YPF is a wholly owned subsidiary of Yara International ASA, which is one of the world's largest producers of nitrogen-based mineral fertilizers.
For the control of the solar power plant, BESS, and electrolyzer, Yokogawa Australia will supply an EMS that is developed by Yokogawa Group company PXiSE Energy Solutions LLC. This EMS will be combined with an integrated control system (ICS) centering on the Collaborative Information Server solution that Yokogawa will also be providing for phase 0 of this project, under a separate contract*1. Once these systems are installed and integrated, the Yuri facility’s renewable energy production will be autonomously managed to ensure consistent stability and power quality based on the operating requirements of the adjacent ammonia plant, the weather, and other factors.
PXiSE’s grid control solutions have already been highly evaluated at a Horizon Power project in Western Australia*2. Horizon Power serves the largest power supply area in the world, and following a successful rollout in Onslow, the solutions will be adopted in 34 additional Horizon Power microgrids. Also, the ability of Yokogawa Australia's Technical Excellence Center in Perth, Western Australia, to provide technical support and engineering services backed by many years of experience in providing cutting-edge solutions to a wide range of industries in Australia was also evaluated.
Commenting on Yokogawa’s participation in this project, Koji Nakaoka, a Yokogawa senior vice president and head of the company's Energy & Sustainability Business Headquarters and Global Sales Headquarters, said, “In a world in which systems are becoming closely integrated, based on the system of systems (SoS) concept, we will contribute to our customer’s ESG management by offering high value-added solutions, including the integration of plant control and energy management systems to enable the timely control of complex power systems.”
*1 Yokogawa to Provide Integrated Control System for Australian Green Hydrogen Project - First-ever use in Australia of green hydrogen as feedstock for ammonia production – https://www.yokogawa.com/news/press-releases/2022/2022-11-30-01/
*2 Horizon Power and PXiSE Energy Solutions Successfully Operate World’s First 100% Solar-Plus-Storage-Only Community Grid https://pxise.com/horizon-power-and-pxise-energy-solutions-successfully-operate-worlds-first-100-solar-plus-storage-only-community-grid/
PXiSE DERMS used in 34 Horizon Power microgrids https://pxise.com/pxise-derms-used-in-34-horizon-power-microgrids/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 129 companies spanning 60 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904401589/en/
Contact information
PR Section
Integrated Communications Center
Yokogawa Electric Corporation
Yokogawa-pr@cs.jp.yokogawa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom